IRadimed Corporation (IRMD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 32 | 42 | 53 | 66 | 73 | 84 | 86 | 92 |
| Operating profit | $m | 26 | 28 | ||||||
| Net profit | $m | 1 | 9 | 13 | 17 | 19 | 22 | 23 | 27 |
| EPS reported | $ | 1.75 | 1.79 | ||||||
| Operating cashflow per share | $ | 1.96 | 2.12 | ||||||
| Capex per share | $ | 0.61 | 0.17 | ||||||
| FCF per share | $ | 1.35 | 1.95 | ||||||
| Free cash flow | $m | 17 | 25 | ||||||
| Net debt | $m | -51 | -59 | ||||||
| Book value equity | $m | 95 | 102 | ||||||
| Book value per share | $ | 7.36 | 7.90 | ||||||
| Number of shares | m | 12.85 | 12.87 | ||||||
| DPS (TTM paid) | $ | 1.18 | 1.27 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 55.59 | 47.91 | ||||||
| P/B LTM | x | 13.08 | 12.16 | ||||||
| P/S LTM | x | 14.77 | 14.33 | ||||||
| P/FCF LTM | x | 72.03 | 49.64 | ||||||
| EV/EBITDA LTM | x | 38.59 | 38.14 | ||||||
| EV/Sales LTM | x | 14.16 | 12.19 | ||||||
| Earnings Yield LTM | % | +1.80% | +2.09% | ||||||
| FCF Yield | % | +1.39% | +2.01% | ||||||
| Quality | |||||||||
| ROE | % | +23.76% | +23.45% | ||||||
| ROIC | % | +21.02% | +20.18% | ||||||
| Operating margin | % | +31.20% | +31.92% | ||||||
| Gross margin | % | +76.75% | +75.86% | ||||||
| FCF/Sales | % | +20.50% | +28.88% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +16.67% | +19.33% | ||||||
| Sales Growth YoY | % | +14.43% | +17.88% | ||||||
| Net Income Growth YoY | % | +16.88% | +19.86% | ||||||
| FCF Growth | % | -2.48% | +41.50% | ||||||
| Operating Profit Growth | % | +19.04% | +25.45% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +1.22% | +1.46% | ||||||
| Dividend Growth | % | +162.22% | +182.22% | ||||||
| Payout Ratio | % | +66.86% | +68.72% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | -1.66 | -1.90 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.54 | -0.58 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free